Perth pharmaceutical company NeuroScientific Biopharmaceuticals (NSB) has announced its lead drug candidate slowed glaucoma-induced damage to the optic nerve, in findings that highlight its potential as a clinically useful treatment.
Read More
NeuroScientific Biopharmaceuticals